PE20211786A1 - Anticuerpos humanizados contra c-kit - Google Patents

Anticuerpos humanizados contra c-kit

Info

Publication number
PE20211786A1
PE20211786A1 PE2021000758A PE2021000758A PE20211786A1 PE 20211786 A1 PE20211786 A1 PE 20211786A1 PE 2021000758 A PE2021000758 A PE 2021000758A PE 2021000758 A PE2021000758 A PE 2021000758A PE 20211786 A1 PE20211786 A1 PE 20211786A1
Authority
PE
Peru
Prior art keywords
kit
seq
nos
human
variable region
Prior art date
Application number
PE2021000758A
Other languages
English (en)
Inventor
Jie Liu
Kavitha Sompalli
Original Assignee
Forty Seven Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forty Seven Inc filed Critical Forty Seven Inc
Publication of PE20211786A1 publication Critical patent/PE20211786A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La invencion proporciona anticuerpos que se unen especificamente a c-Kit humano que comprende una region variable pesada madura que comprende las CDR H1, H2 y H3 segun lo definido por Kabat de SEQ ID NOS: 2-4 respectivamente, y una region variable de cadena ligera madura que comprende las CDR L1, L2 y L3 de SEQ ID NOS: 6-8 respectivamente. Dicho anticuerpo tiene una union mejorada a c-Kit humano en relacion con AMG191. Tambien refiere a una composicion farmaceutica que lo contiene, siendo util para la ablacion de celulas endogenas en la terapia de reemplazo de celulas madre y en el tratamiento del cancer
PE2021000758A 2018-11-26 2019-11-25 Anticuerpos humanizados contra c-kit PE20211786A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862771526P 2018-11-26 2018-11-26
PCT/US2019/063091 WO2020112687A2 (en) 2018-11-26 2019-11-25 Humanized antibodies against c-kit

Publications (1)

Publication Number Publication Date
PE20211786A1 true PE20211786A1 (es) 2021-09-09

Family

ID=70769872

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000758A PE20211786A1 (es) 2018-11-26 2019-11-25 Anticuerpos humanizados contra c-kit

Country Status (18)

Country Link
US (3) US11208482B2 (es)
EP (1) EP3817773A4 (es)
JP (2) JP7166457B2 (es)
KR (1) KR20210094610A (es)
CN (1) CN113194991A (es)
AU (1) AU2019386976A1 (es)
CA (1) CA3117816A1 (es)
CL (1) CL2021001366A1 (es)
CO (1) CO2021006869A2 (es)
CR (1) CR20210272A (es)
DO (1) DOP2021000101A (es)
EA (1) EA202190986A1 (es)
IL (1) IL282668A (es)
MX (1) MX2021006134A (es)
PE (1) PE20211786A1 (es)
PH (1) PH12021551126A1 (es)
SG (1) SG11202104441QA (es)
WO (1) WO2020112687A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202190986A1 (ru) 2018-11-26 2021-12-14 Фоти Севен, Инк. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К c-Kit
CN113166727A (zh) 2018-11-28 2021-07-23 四十七公司 对消融方案耐受的基因修饰的hspc
JP2022533253A (ja) * 2019-05-24 2022-07-21 フォーティ セブン， インコーポレイテッド ｃ－ｋｉｔ及びＣＤ４７に対する免疫療法剤の同時投与レジメン
BR112022014623A2 (pt) 2020-02-14 2022-09-13 Jounce Therapeutics Inc Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
US20240115615A1 (en) * 2021-02-09 2024-04-11 Jasper Therapeutics, Inc. Modified stem cell compositions and methods for use
WO2023069961A1 (en) * 2021-10-18 2023-04-27 Jasper Therapeutics, Inc. Modified stem cell compositions and methods for use
WO2023111311A1 (en) 2021-12-16 2023-06-22 Universität Basel Discernible cell surface protein variants of cd117 for use in cell therapy
KR102572039B1 (ko) * 2022-04-18 2023-08-30 주식회사 노벨티노빌리티 슈도모나스 외독소 A를 포함하는 c-Kit 표적 면역접합체
WO2024008910A1 (en) 2022-07-07 2024-01-11 Cimeio Therapeutics Ag Antibodies targeting cd117
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US5821108A (en) 1995-04-07 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Enrichment for a thymocyte subset having progenitor cell activity using c-kit as a selection marker
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
ATE490518T1 (de) 1999-02-05 2010-12-15 Samsung Electronics Co Ltd Verfahren und vorrichtung zum wiederauffinden von texturbildern
EP1539233B1 (en) 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
MXPA05005481A (es) 2002-11-29 2005-07-25 Boehringer Ingelheim Pharma Nuevos genes de la fosfotransferasa de neomicina y procedimiento para la seleccion de celulas recombinantes de produccion elevada.
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
JP4620739B2 (ja) 2004-11-10 2011-01-26 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Ｃｈｏ細胞に対する細胞保存戦略を最適化するためのフローサイトメトリ分析の使用
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
WO2008067115A2 (en) 2006-11-03 2008-06-05 The Board Of Trustees Of The Leland Stanford Junior University Selective immunodepletion of endogenous stem cell niche for engraftment
MX2009009156A (es) 2007-03-02 2009-09-04 Boehringer Ingelheim Pharma Mejora de la produccion de proteina.
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
EP4160212B1 (en) 2008-01-15 2024-04-17 The Board of Trustees of the Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
ES2582340T3 (es) 2008-01-15 2016-09-12 The Board Of Trustees Of The Leland Stanford Junior University Métodos para manipular fagocitosis mediada por CD47
CN102481340A (zh) * 2009-05-28 2012-05-30 葛兰素集团有限公司 干细胞靶向
AU2010295661B2 (en) 2009-09-15 2015-04-30 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-CD47 therapy for hematologic cancers
WO2011059972A1 (en) 2009-11-10 2011-05-19 The Board Of Trustees Of The Leland Stanford Junior University Cell surface marker expression in hematopoietic stem cells and progenitors for the diagnosis, prognosis, and treatment of myelodysplastic syndromes
WO2011143624A2 (en) 2010-05-14 2011-11-17 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd47
AR086044A1 (es) * 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
NZ628433A (en) 2012-01-20 2017-02-24 Immunophotonics Inc Chitosan-derived compositions
NZ630363A (en) * 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
JP6255408B2 (ja) 2012-09-25 2017-12-27 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 治療システム
SG11201506451UA (en) * 2013-03-06 2015-09-29 Merrimack Pharmaceuticals Inc Anti-c-met tandem fc bispecific antibodies
NZ710929A (en) * 2013-03-15 2018-02-23 Novartis Ag Antibody drug conjugates
AR100280A1 (es) * 2014-05-22 2016-09-21 Rohm & Haas Aglutinantes poliméricos para impresoras de chorro de tinta
WO2016020791A1 (en) * 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
WO2016033201A1 (en) 2014-08-26 2016-03-03 The Board Of Trustees Of The Leland Stanford Junior University Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling
CA2982115A1 (en) 2015-04-06 2016-10-13 President And Fellows Of Harvard College Compositions and methods for non-myeloablative conditioning
WO2016179399A1 (en) 2015-05-06 2016-11-10 The Board Of Trustees Of The Leland Stanford Junior University High affinity cd47 analogs
WO2016187226A1 (en) 2015-05-18 2016-11-24 Ab Initio Biotherapeutics, Inc. Sirp polypeptide compositions and methods of use
CN109152837A (zh) 2016-04-15 2019-01-04 小利兰·斯坦福大学托管委员会 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法
SG10202100726XA (en) * 2016-06-17 2021-02-25 Magenta Therapeutics Inc Compositions and methods for the depletion of cd117+cells
JOP20190155A1 (ar) * 2016-12-21 2019-06-23 Novartis Ag مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم
IL301075B1 (en) 2017-01-30 2024-01-01 Univ Leland Stanford Junior A non-genotoxic matching regimen for stem cell transplantation
CN110831974A (zh) 2017-06-21 2020-02-21 小利兰·斯坦福大学托管委员会 针对血液恶性肿瘤的cd47靶向疗法的给药参数
US10961318B2 (en) 2017-07-26 2021-03-30 Forty Seven, Inc. Anti-SIRP-α antibodies and related methods
EA202190986A1 (ru) 2018-11-26 2021-12-14 Фоти Севен, Инк. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К c-Kit
CN113166727A (zh) 2018-11-28 2021-07-23 四十七公司 对消融方案耐受的基因修饰的hspc
JP2022533253A (ja) 2019-05-24 2022-07-21 フォーティ セブン， インコーポレイテッド ｃ－ｋｉｔ及びＣＤ４７に対する免疫療法剤の同時投与レジメン

Also Published As

Publication number Publication date
DOP2021000101A (es) 2021-09-30
CA3117816A1 (en) 2020-06-04
WO2020112687A3 (en) 2020-08-20
EA202190986A1 (ru) 2021-12-14
CL2021001366A1 (es) 2021-11-19
US11041022B2 (en) 2021-06-22
CN113194991A (zh) 2021-07-30
US20210122822A1 (en) 2021-04-29
EP3817773A2 (en) 2021-05-12
MX2021006134A (es) 2021-06-23
WO2020112687A2 (en) 2020-06-04
US11208482B2 (en) 2021-12-28
JP7166457B2 (ja) 2022-11-07
JP2022507962A (ja) 2022-01-18
US20200165337A1 (en) 2020-05-28
JP2022137208A (ja) 2022-09-21
CO2021006869A2 (es) 2021-06-10
EP3817773A4 (en) 2021-09-15
SG11202104441QA (en) 2021-06-29
US20220127358A1 (en) 2022-04-28
IL282668A (en) 2021-06-30
PH12021551126A1 (en) 2022-02-21
AU2019386976A1 (en) 2021-06-03
KR20210094610A (ko) 2021-07-29
CR20210272A (es) 2021-07-14

Similar Documents

Publication Publication Date Title
PE20211786A1 (es) Anticuerpos humanizados contra c-kit
CY1121148T1 (el) Παραγοντες συνδεσης vegf/dll4 και χρησεις αυτων
PE20170953A1 (es) ANTICUERPOS ANTI-CD79b Y METODOS DE USO
NZ738979A (en) Pd-1 antibodies
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
AR091605A1 (es) Proteinas de union anti-mesotelina
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
EA201792221A1 (ru) Антитела против сортилина и способы их применения
PE20210180A1 (es) Anticuerpos anti-cd33, anticuerpos biespecificos anti-cd33/anti-cd3 y usos de estos
CL2021000873A1 (es) Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas.
PE20150002A1 (es) Anticuerpos anti-fcrn
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
PE20161389A1 (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
PE20120899A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
EA201490957A1 (ru) Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
EA201590085A1 (ru) Антитела анти-egfr и их применение
MX2021004808A (es) Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos.
EA201891925A1 (ru) Антитела к cd40 с усиленной агонистической активностью
PE20171107A1 (es) Anticuerpos mejorados contra il-6
CO2020006865A2 (es) Composiciones y métodos para el agotamiento de células cd5+
EA202091557A1 (ru) Антитела, содержащие только тяжелые цепи, которые связываются с cd22
EA202092420A1 (ru) Антитело против pd-l1 и его применение
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
EA201992326A1 (ru) Композиции и способы оказания направленного воздействия на альфа-v бета-3-положительные раковые стволовые клетки (csc) и лечения (avb3) лекарственно-устойчивых видов рака